Acceleron Pharma Inc. (XLRN) and Unity Biotechnology Inc. (NASDAQ:UBX) Comparison side by side

Acceleron Pharma Inc. (NASDAQ:XLRN) and Unity Biotechnology Inc. (NASDAQ:UBX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 43 61.35 N/A -2.76 0.00
Unity Biotechnology Inc. 8 0.00 N/A -2.18 0.00

In table 1 we can see Acceleron Pharma Inc. and Unity Biotechnology Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. 0.00% -35.9% -33.4%
Unity Biotechnology Inc. 0.00% -46.4% -42.4%


19.3 and 19.3 are the respective Current Ratio and a Quick Ratio of Acceleron Pharma Inc. Its rival Unity Biotechnology Inc.’s Current and Quick Ratios are 13.7 and 13.7 respectively. Acceleron Pharma Inc. has a better chance of clearing its pay short and long-term debts than Unity Biotechnology Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Acceleron Pharma Inc. and Unity Biotechnology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 2 3 2.60
Unity Biotechnology Inc. 0 0 1 3.00

The consensus target price of Acceleron Pharma Inc. is $60.4, with potential upside of 38.63%. Competitively the consensus target price of Unity Biotechnology Inc. is $21, which is potential 252.94% upside. The information presented earlier suggests that Unity Biotechnology Inc. looks more robust than Acceleron Pharma Inc. as far as analyst opinion.

Insider & Institutional Ownership

Roughly 93.6% of Acceleron Pharma Inc. shares are held by institutional investors while 72.8% of Unity Biotechnology Inc. are owned by institutional investors. Acceleron Pharma Inc.’s share held by insiders are 0.6%. Competitively, 8.3% are Unity Biotechnology Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 2.78% 3.39% 9.2% 4.8% 4% 0.25%
Unity Biotechnology Inc. -5.11% -26.69% -12.95% -38.23% -51.94% -56.58%

For the past year Acceleron Pharma Inc. had bullish trend while Unity Biotechnology Inc. had bearish trend.


Acceleron Pharma Inc. beats on 6 of the 9 factors Unity Biotechnology Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.